## Shuichiro Shiina

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5896157/publications.pdf

Version: 2024-02-01

218677 138484 6,936 61 26 58 citations h-index g-index papers 62 62 62 6238 all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatology International, 2017, 11, 317-370.	4.2	1,537
2	A Randomized Controlled Trial of Radiofrequency Ablation With Ethanol Injection for Small Hepatocellular Carcinoma. Gastroenterology, 2005, 129, 122-130.	1.3	831
3	Percutaneous radiofrequency ablation for hepatocellular carcinoma. Cancer, 2005, 103, 1201-1209.	4.1	756
4	Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic Factors. American Journal of Gastroenterology, 2012, 107, 569-577.	0.4	604
5	Sarcopenia, intramuscular fat deposition, and visceral adiposity independently predict the outcomes of hepatocellular carcinoma. Journal of Hepatology, 2015, 63, 131-140.	3.7	538
6	Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology, 1995, 22, 1027-1033.	7.3	336
7	Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update. Liver Cancer, 2021, 10, 181-223.	7.7	307
8	Des-?-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma. Cancer, 2001, 91, 561-569.	4.1	295
9	Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology, 1995, 22, 1027-1033.	7.3	192
10	Nonsurgical Treatment of Hepatocellular Carcinoma: From Percutaneous Ethanol Injection Therapy and Percutaneous Microwave Coagulation Therapy to Radiofrequency Ablation. Oncology, 2002, 62, 64-68.	1.9	166
11	Detection of α-fetoprotein mRNA, an indicator of hematogenous spreading hepatocellular carcinoma, in the circulation: A possible predictor of metastatic hepatocellular carcinoma. Hepatology, 1994, 20, 1418-1425.	7.3	137
12	Risk factors for recurring hepatocellular carcinoma differ according to infected hepatitis virus-An analysis of 236 consecutive patients with a single lesion. Hepatology, 2000, 32, 1216-1223.	7.3	125
13	Modulation of hepatotoxicity by macrophages in the liver. Hepatology, 1988, 8, 815-821.	7.3	118
14	Percutaneous Ablation for Hepatocellular Carcinoma: Comparison of Various Ablation Techniques and Surgery. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-8.	1.9	84
15	Machine-learning Approach for the Development of a Novel Predictive Model for the Diagnosis of Hepatocellular Carcinoma. Scientific Reports, 2019, 9, 7704.	3.3	82
16	The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. Journal of Hepatology, 2016, 65, 1272-1273.	3.7	79
17	Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy. Journal of Hepatology, 2019, 70, 78-86.	3.7	71
18	Percutaneous ethanol injection for hepatocellular carcinoma: 20â€year outcome and prognostic factors. Liver International, 2012, 32, 1434-1442.	3.9	69

#	Article	IF	CITATIONS
19	Role of endotoxin-responsive macrophages in hepatic injury. Hepatology, 1990, 11, 183-192.	7.3	66
20	Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-?-carboxy prothrombin and low serum ?-fetoprotein. Cancer, 2000, 88, 1557-1564.	4.1	60
21	Production of chemotactic factor, interleukin-8, from hepatocytes exposed to ethanol. Hepatology, 1993, 18, 1477-1482.	7.3	44
22	Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines. Hepatology International, 2011, 5, 890-898.	4.2	35
23	Role of polymorphonuclear leukocytes in galactosamine hepatitis: Mechanism of adherence to hepatic endothelial cells. Hepatology, 1994, 20, 1548-1556.	7.3	34
24	Small hyperechoic nodules in chronic liver diseases include hepatocellular carcinomas with low cyclin D1 and Ki-67 expression. Hepatology, 1999, 29, 1722-1729.	7.3	33
25	Image-guided percutaneous ablation therapies for hepatocellular carcinoma. Journal of Gastroenterology, 2009, 44, 122-131.	5.1	28
26	Response Evaluation Criteria in Cancer of the Liver versionÂ5 (RECICL 2019 revised version). Hepatology Research, 2019, 49, 981-989.	3.4	27
27	Inhibition of hepatic metastasis of colon carcinoma by asialo GM1–positive cells in the liver. Hepatology, 1992, 16, 469-478.	7.3	26
28	APASL practical recommendations for the management of hepatocellular carcinoma in the era of COVID-19. Hepatology International, 2020, 14, 920-929.	4.2	24
29	Frequency of and Predictive Factors for Vascular Invasion after Radiofrequency Ablation for Hepatocellular Carcinoma. PLoS ONE, 2014, 9, e111662.	2.5	24
30	Poor association of TT virus viremia with hepatocellular carcinoma. Liver International, 2000, 20, 247-252.	3.9	17
31	Effect of Diameter and Number of Hepatocellular Carcinomas on Survival After Resection, Transarterial Chemoembolization, and Ablation. American Journal of Gastroenterology, 2021, 116, 1698-1708.	0.4	17
32	Comparison of improved prognosis between hepatitis B―and hepatitis Câ€related hepatocellular carcinoma. Hepatology Research, 2015, 45, E99-E107.	3.4	15
33	Collaterals in portal hypertension: anatomy and clinical relevance. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3867-3881.	2.0	15
34	Impact of serum ferritin level on hepatocarcinogenesis in chronic hepatitis C patients. Hepatology Research, 2016, 46, 259-268.	3.4	13
35	An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma. Hepatology International, 2014, 8, 94-103.	4.2	11
36	Al-Based Radiological Imaging for HCC: Current Status and Future of Ultrasound. Diagnostics, 2021, 11, 292.	2.6	11

3

#	Article	IF	CITATIONS
37	Hepatocellular carcinoma depicted as hypoattenuation on CT hepatic arteriography (CTA) and hyperattenuation on CT during arterial portography (CTAP). Journal of Gastroenterology, 2001, 36, 346-349.	5.1	10
38	Drastically Reduced Neoplastic Seeding Related to Radiofrequency Ablation for Hepatocellular Carcinoma. American Journal of Gastroenterology, 2014, 109, 774-776.	0.4	10
39	Slight elevation of highâ€sensitivity <scp>C</scp> â€reactive protein to predict recurrence and survival in patients with early stage hepatitis <scp>C</scp> â€related hepatocellular carcinoma. Hepatology Research, 2015, 45, 645-655.	3.4	10
40	Incidence and hemodynamic feature of risky esophageal varices with lower hepatic venous pressure gradient. International Journal of Medical Sciences, 2019, 16, 1614-1620.	2.5	10
41	Expression of c-Met in Primary and Recurrent Hepatocellular Carcinoma. Oncology, 2020, 98, 186-194.	1.9	10
42	Japanese experience in ablation therapies for hepatocellular carcinoma. Hepatology Research, 2007, 37, S223-S229.	3.4	6
43	Efficacy of recombinant human soluble thrombomodulin in patients with sepsis and disseminated intravascular coagulation in the gastroenterology field. Biomedical Reports, 2015, 3, 457-460.	2.0	6
44	Characteristics of hepatocellular carcinoma nodules newly detected by computed tomography during arteriography and arterial portography: preliminary report of a randomized controlled trial. Hepatology International, 2012, 6, 639-645.	4.2	5
45	Best Procedure for the Management of Common Bile Duct Stones via the Papilla: Literature Review and Analysis of Procedural Efficacy and Safety. Journal of Clinical Medicine, 2020, 9, 3808.	2.4	5
46	Serum levels of ferritin do not affect the prognosis of patients with hepatocellular carcinoma undergoing radiofrequency ablation. PLoS ONE, 2018, 13, e0200943.	2.5	4
47	Ischemic complications after percutaneous radiofrequency ablation of liver tumors: Liver volume loss and recovery. Hepatology Research, 2019, 49, 453-461.	3.4	4
48	Production of chemotactic factor, interleukin-8, from hepatocytes exposed to ethanol. Hepatology, 1993, 18, 1477-1482.	7.3	4
49	Local ablation therapy for hepatocellular carcinoma. From ethanol injection to radiofrequency ablation. Journal of King Abdulaziz University, Islamic Economics, 2007, 28, 831-7.	1.1	4
50	Improved prognosis of hepatitis Câ€related hepatocellular carcinoma in the era of directâ€acting antivirals. Hepatology Communications, 2022, 6, 2496-2512.	4.3	4
51	Contrast-enhanced ultrasonography: is it an ideal tool for hepatocellular carcinoma surveillance?. Quantitative Imaging in Medicine and Surgery, 2019, 9, 1611-1614.	2.0	3
52	Clinical Evaluation of a Newly Developed Guidewire for Pancreatobiliary Endoscopy. Journal of Clinical Medicine, 2020, 9, 4059.	2.4	3
53	Radiofrequency Ablation of Liver Tumors in Patients on Antithrombotic Therapy: A Case-Control Analysis of over 10,000 Treatments. Journal of Vascular and Interventional Radiology, 2021, 32, 869-877.	0.5	3
54	Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH). European Radiology Experimental, 2020, 4, 3.	3.4	3

## SHUICHIRO SHIINA

#	Article	IF	CITATIONS
55	Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics. PLoS ONE, 2021, 16, e0259641.	2.5	2
56	Efficacy and Safety of Deep Sedation in Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma. Advances in Therapy, 2019, 36, 344-354.	2.9	1
57	Antioxidant therapy on ischemic hepatitis: here we are and where do we go?. Hepatology International, 2020, 14, 456-459.	4.2	1
58	A case of pancreatoblastoma in which EUS-FNA aided the diagnosis. Suizo, 2015, 30, 689-696.	0.1	1
59	A case of simultaneous abdominal wall metastasis of hepatocellular carcinoma with long-term relapse-free survival after laparoscopic resection. International Cancer Conference Journal, 2021, 10, 217-221.	0.5	O
60	Connection between HPS and ACLF: a solution of chaos?. Hepatology International, 2021, 15, 1049-1052.	4.2	0
61	A case of more than 10-year survival of locally advanced unresectable pancreatic head cancer treated with chemoradiotherapy. Suizo, 2016, 31, 841-848.	0.1	0